What traders can verify, and what they can't
The oncology story is bullish, and parts of it hold up. A personalized vaccine developed by Merck and Moderna stopped melanoma from returning in a clinical trial described as historic.1 Detailed results of that vaccine, intismeran, are due at ESMO on October 24, with the companies also planning to engage regulators about potential filings.2 A second dated catalyst is the FDA's PDUFA goal date of November 14, 2026 for Summit's ivonescimab application, which is based on the HARMONi trial.3
Two caveats come first. The dossier holds the event headline for the vaccine, not the trial's numbers: no response rate, hazard ratio or patient count. That detail is exactly what ESMO is meant to supply, so until October 24 nobody outside the trial can size the effect. Separately, the narrative behind this piece says second-quarter guidance was raised at oncology-heavy companies (Hematology and Oncology, Opzelura, Kiniksa). We could not trace that to a source document, so we treat it as an unverified claim.
Merck: the checked numbers are less cheerful than the headline
Merck is the one company here where we hold SEC-filing data that has been checked against its source. We cannot say how much of any index fund is Merck, because the dossier contains no weighting, so we won't guess. What the filings show is a company spending heavily and holding less cash than it recently did.
Cash at the end of fiscal 2025 was $14.565 billion, and at the end of the third quarter of 2025 it was $18.169 billion.4 By the end of the first quarter of 2026 it had fallen to $5.327 billion, and at the end of the second quarter of 2026 it was $6.849 billion.4 So cash dropped by more than half within one quarter and has only partly recovered. The filings do not say why, and we won't speculate. Cash balances at quarter-end also swing for many ordinary reasons, so this is a fact to watch rather than proof of a problem. For scale, the second-quarter 2026 balance is below the $8.007 billion Merck held a year earlier.4
Costs are rising too. Cost of revenue, the direct cost of producing what the company sells, was $4.395 billion in the second quarter of 2026, against $3.557 billion in the second quarter of 2025.4 That is an increase of about 24%. The first quarter shows a similar pattern: $4.195 billion in 2026 against $3.419 billion in 2025.4 The dossier has no revenue figures for the same periods. We therefore cannot say whether costs are growing faster than sales, which is the question that matters. Anyone citing a margin for Merck from this material would be inventing it.
Capital spending, the money spent on plants and equipment, was $4.112 billion for fiscal 2025, up from $3.372 billion in 2024 and still above $3.863 billion in 2023.4 In the first quarter of 2026 it was $991 million, down from $1.328 billion a year earlier, about a quarter lower.4 That is a slower start to the year, but one quarter is not a trend.
Evidence that the commercial side is working
The strongest hard evidence in the dossier comes from Novocure rather than from the vaccine. Novocure reported second-quarter 2026 net revenues of $184 million, up 16% year over year, with 18% growth in global active patients.5 It also received a CE Mark for Optune Pax in locally advanced pancreatic cancer, and more than 280 patients were active on that product by June 30.5 CEO Frank Leonard said: "This was our strongest quarter to date, with record net revenues and active patients on therapy."5 That is a company statement. The figures come from its own results release, which fits the narrative that oncology demand is real.
The AI-biologics leg is the least tested
The AI side of the thesis rests on one source: an MIT Technology Review piece in which Puja Sapra describes AstraZeneca's approach. It is the weakest evidence in the dossier. Our checks found that 0% of 11 claims checked from that document held up.6 That is a small sample and a poor result, and the piece is undated in our records, though its excerpt carries a July 23, 2026 header. We use it for what AstraZeneca says it is trying to do, not as proof that it works.
On strategy, Sapra says: "Data is our differentiator."6 On the pitch for automated labs, she says such systems "will generate AI-ready data at a scale that traditional workflows cannot match."6 The most useful line for anyone sizing this theme is her admission of the hard part: "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."6 She also says human oversight "remains at the heart of this approach."6 Nothing in the dossier gives a drug, a date or a trial result attributable to AI-designed biologics. Via News's reading is that this is a stated direction, not yet a catalyst.
Smaller biotechs: runways and deals
The weekly sector roundup shows the gap between large and small companies. ADC Therapeutics says it "maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations."8 The same headline also records job cuts at the company, so a long runway came with cost-cutting.8 That roundup's source scores 45% on our reliability check across 520 claims.8
Treeline Biosciences is taking a different route, a transaction with Standard BioTools. The combined company expects over $900 million at closing and reports Phase 1 TLN-121 results in relapsed or refractory lymphoma: a 84% overall response rate, a 32% complete response rate and no observed dose-limiting toxicities.7 Treeline's Josh Bilenker said the cash "will help us accelerate the development of our clinical programs."7 Treat these as company-reported early-stage numbers. The source feed behind them held up on only 31% of 2,925 checked claims, so we would verify them against the registration statement before acting.7
Other oncology items on the calendar
Telix dosed the first patient in the Phase 3 LUTEON trial of TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma, described as the first radiopharmaceutical therapy to enter Phase 3 for that cancer.9 In Europe, the CHMP recommended Gilead's Trodelvy plus Keytruda for first-line PD-(L)1-positive metastatic triple-negative breast cancer. The release says a second first-line approval would establish Trodelvy as a backbone therapy across PD-L1 status in the EU.10 Both releases come from news feeds with measured reliability of 31% and 57% respectively, so the claims should be read as company statements.9,10
What to watch
- October 24: ESMO data for intismeran. Look for actual effect sizes and whether regulatory filings are confirmed.2
- November 14: the FDA decision date for ivonescimab.3
- Merck's next filing: whether cash rebuilds from $6.849 billion and whether cost of revenue keeps growing about 24% a year.4
- Smaller biotechs: whether runways like ADC Therapeutics' into 2028 hold, and whether Treeline's transaction closes.7,8
In short, there are three dated catalysts and one strongly verified commercial result. The AI-biologics story is, for now, a stated strategy with weak sourcing.
